Wells Fargo’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $334K | Sell |
16,656
-1,057
| -6% | -$21.2K | ﹤0.01% | 4058 |
|
|
2025
Q1 | $349K | Buy |
17,713
+1,047
| +6% | +$20.6K | ﹤0.01% | 3903 |
|
|
2024
Q4 | $375K | Buy |
16,666
+5,548
| +50% | +$125K | ﹤0.01% | 3908 |
|
|
2024
Q3 | $284K | Sell |
11,118
-371
| -3% | -$9.48K | ﹤0.01% | 3968 |
|
|
2024
Q2 | $268K | Buy |
11,489
+3,274
| +40% | +$76.5K | ﹤0.01% | 3964 |
|
|
2024
Q1 | $145K | Buy |
8,215
+1,057
| +15% | +$18.6K | ﹤0.01% | 4305 |
|
|
2023
Q4 | $99.1K | Buy |
7,158
+1,418
| +25% | +$19.6K | ﹤0.01% | 4502 |
|
|
2023
Q3 | $78.4K | Sell |
5,740
-3,130
| -35% | -$42.8K | ﹤0.01% | 4586 |
|
|
2023
Q2 | $181K | Buy |
8,870
+8,846
| +36,858% | +$181K | ﹤0.01% | 4391 |
|
|
2023
Q1 | $526 | Hold |
24
| – | – | ﹤0.01% | 6224 |
|
|
2022
Q4 | $397 | Hold |
24
| – | – | ﹤0.01% | 6115 |
|
|
2022
Q3 | $0 | Buy |
24
+3
| +14% | – | ﹤0.01% | 6481 |
|
|
2022
Q2 | $0 | Buy |
21
+1
| +5% | – | ﹤0.01% | 6648 |
|
|
2022
Q1 | $0 | Hold |
20
| – | – | ﹤0.01% | 6785 |
|
|
2021
Q4 | $0 | Hold |
20
| – | – | ﹤0.01% | 6770 |
|
|
2021
Q3 | $0 | Buy |
20
+12
| +150% | – | ﹤0.01% | 6717 |
|
|
2021
Q2 | $0 | Sell |
8
-576
| -99% | – | ﹤0.01% | 6633 |
|
|
2021
Q1 | $20K | Sell |
584
-383
| -40% | -$13.1K | ﹤0.01% | 5789 |
|
|
2020
Q4 | $85K | Buy |
967
+562
| +139% | +$49.4K | ﹤0.01% | 5244 |
|
|
2020
Q3 | $33K | Sell |
405
-285
| -41% | -$23.2K | ﹤0.01% | 5370 |
|
|
2020
Q2 | $76K | Buy |
+690
| New | +$76K | ﹤0.01% | 5118 |
|